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$50,000 per QALY. CONCLUSION: It cannot be conﬁdently
concluded that either H. pylori screening was a cost-effective
strategy compared to no screening in all Chinese at age of 40
years. Nevertheless, serology screening has demonstrated much
more potentiality to be a cost-effective strategy, especially in the
population with higher gastric cancer prevalence.
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OBJECTIVE: To develop a claims-based Markov model for
Crohn’s disease (CD) based on the American College of Gastro-
enterology (ACG) criteria. METHODS: A Markov model was
developed using disease states as deﬁned by ACG CD practice
guidelines. The study sample consisted of unique individuals18
years old from the Medstat Marketscan databases (Medicare and
Commercial) with3 years of continuous enrollment from 2000–
2005, and with an ICD-9 diagnosis code of 555.xx. Patients were
classiﬁed as severe-fulminant, moderate-severe, mild-moderate,
or remission based on the ACG criteria. Patient exposure was
divided into six month intervals, starting on ﬁrst day of exposure.
For each interval, disease state was deﬁned according to the most
severe disease activity. Transition probabilities between disease
states were calculated based on movement from one six month
period to the next. Costs of disease states were calculated using
mean per member per month (PMPM) medical claim costs, and
the model was run separately for males and females due to
differences in life expectancy, assuming 30 years old at start.
Quality-adjusted life year (QALY) estimates were obtained from
the literature. RESULTS: There were 23,419 unique individuals,
with 198,497 eligible 6-month intervals. The distribution of
disease states were: remission (99,584; 50.2%), mild-moderate
(24,788; 12.5%), moderate-severe (56,686; 28.6%), severe-
fulminant (17,439; 8.8%). Model results for both males and
females showed that, as disease severity increased, cost per QALY
also increased. Cost per QALY for mild-moderate disease in males
was $4,310 whereas for severe-fulminant disease, it was $68,538.
Results were similar for females ($4,311 vs. $68,643).CONCLU-
SION: Results of this model indicate that cost of CD increases as
disease severity increases. In addition, although less time is spent
in the severe disease state, the cost per QALYwas high, suggesting
that therapies that can keep patients in other disease states may
prove to be beneﬁcial.
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OBJECTIVE: To assess utilization and costs of health care ser-
vices for patients diagnosed with gastroesophageal reﬂux disease
(GERD) that were dispensed once (QD) vs. twice (BID) daily
PPIs. METHODS: Employing Thomson’s MarketScan Database,
GERD patients 18+ years of age with 1+ PPI dispensed, but had
no esophagitis or Barrett’s esophagus diagnosed during 2003–
2004 were selected. The date of the ﬁrst observed PPI was con-
sidered as the index date. Frequency of PPI dosing (QD vs. BID)
was assessed from pharmacy claims. Differences in total and
GERD-related costs by cohort for the 12-month period following
the index date were assessed using multivariate regression,
adjusting for demographic and clinical characteristics (age,
gender, region, Charlson comorbidity score [CCS], pre-index
diagnosis of esophageal stricture or hemorrhage [ESH], and pre-
index use of PPIs). RESULTS: A total of 219,365 GERD patients
on QD PPI therapy and 23,011 patients on BID PPI therapy were
identiﬁed. The cohorts were similar in age, but the QD cohort
had a larger proportion of males (41% vs. 37%, p < 0.01). Mean
CCS was higher in the BID cohort (1.2 vs. 1.0, p < 0.01). A
higher proportion of BID patients had pre-index ESH diagnosed
(4% vs.3%, p < 0.01) and PPI’s dispensed (58% vs. 47%,
p < 0.01). In the 12-month follow up period, the mean number of
ofﬁce visits was higher among BID patients (14.5 vs. 12.4,
p < 0.01). Total health care payments were about $2900 higher
for BID patients ($11,102 vs. $8,169, p < 0.01), 55% of which
were payments for services. GERD-related costs were about
$750 higher for BID patients ($1941 vs. $1187, p < 0.01). On an
adjusted basis, total and GERD-related payments were approxi-
mately $1500 and $450 higher among the BID cohort. CON-
CLUSION: Findings indicate that patients diagnosed with GERD
who receive BID PPI therapy incur more and GERD-related
health care resource utilization and plan payments relative to
those on QD therapy.
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OBJECTIVE: Both constipation (C) and irritable bowel syn-
drome plus C (IBS+C) are known to be very costly. However, it is
unknown whether the costs of C are driven by the same factors
that drive the costs of IBS+C. We aimed to assess the cost of
illness (COI) for C without and with IBS (IBS+C) by point of
service. METHODS: A retrospective analysis was conducted
using multiple US-based employers’ health claims data from
2001–2005. Data included medical, pharmacy, payroll, and
demographics. ICD-9 Codes were used to include employees in
the C cohort: 564.0 (Constipation), 564.00 (Unspeciﬁed), 564.01
(Slow Transit), and 564.09 (Other). Employees with C and an
ICD-9 for IBS (564.1x) at any time were included in the IBS+C
cohort. Propensity-scores based on demographics, job-related
variables, region, existence of medical claims, and Charlson
Comorbidity Index Score were used to match ﬁve C to each
IBS+C cohort employee. For both cohorts, the index date was the
date of the ﬁrst claim for the condition. Per member per month
(PMPM) costs (adjusted to 2006 US$) were compared for each
category based on claims from: doctor’s ofﬁce, inpatient hospital,
outpatient hospital/clinic, emergency department (ED), labora-
tory, other locations, and pharmacy. Costs were compared
between groups before diagnosis, after diagnosis, and change
(before-after). RESULTS: Data were available for 203 persons
with IBS+C and 1015 propensity-score-matched C subjects.
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